慕尼黑Valsalva植入技术(MuVIT)在标准与复杂胸主动脉腔内修复术中降低心输出量的首次应用经验
该单中心回顾性队列研究评估了MuVIT在标准及开窗/分支TEVAR中降低心输出量的技术成功率和安全性。40例患者中,近端支架释放技术成功率为100%,目标收缩压下降在95%的病例中达成。30天死亡率为7.5%,与MuVIT无关;两名COPD Gold III/IV患者出现呼吸系统并发症。
要点
- MuVIT在标准及复杂TEVAR中近端支架释放技术成功率为100%。
- 目标收缩压下降总体达成率为95%(Group 1为89.5%,Group 2为100%)。
- 30天死亡率为7.5%,与MuVIT无关;两名COPD Gold III/IV患者出现呼吸系统并发症。
核心结论
- MuVIT是主动脉弓TEVAR中降低心输出量的安全有效手法,但需谨慎选择患者,对严重COPD患者的潜在不良影响需进一步评估。
研究设计与样本
- 该研究为回顾性单中心队列研究,纳入2020年3月至2021年2月期间接受标准及开窗/分支TEVAR(fbTEVAR)并使用MuVIT降低心输出量的患者。
主要发现
- 研究期间筛查52例,40例(77%)在MuVIT下完成手术;排除原因包括局部麻醉(n=9)、肺部禁忌(n=2)和心脏泵功能差(n=1)。
- 15例(37.5%)接受bTEVAR,3例(7.5%)接受fTEVAR,22例(55%)接受标准TEVAR;29例(72.5%)为择期,7例(17.5%)为紧急,4例(10%)为急诊。
- MuVIT下近端支架释放成功率为100%;目标收缩压下降达成率为95%(Group 1为89.5%,Group 2为100%),总体平均下降46%(Group 1为55%,Group 2为40%)。
- 30天死亡率为7.5%,与MuVIT无关;两名COPD Gold III/IV患者出现呼吸系统并发症。
关键数值与推荐
- Group 1(Ishimaru 0-1区近端锚定)目标收缩压下降50%,Group 2(Ishimaru 2-3区锚定)目标收缩压下降30%。
- 疗效结局包括MuVIT技术成功和手术技术成功;安全性结局包括30天内MuVIT及手术相关并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Munich Valsalva Implantation Technique (MuVIT) is a non-invasive alternative which uses a modified Valsalva manoeuvre to reduce cardiac output (CO). The aim of this study was to evaluate the technical success and safety of MuVIT in standard and complex endovascular thoracic aneurysm repair (TEVAR). METHODS: This was a retrospective single centre cohort study. Patients were included who underwent CO reduction with MuVIT between March 2020 and February 2021 for standard and fenestrated/branched TEVAR (fbTEVAR). The target systolic blood pressure (SBP) reduction was used as an indicator of CO reduction. The aim of the SBP reduction was 50% in patients undergoing proximal sealing in Ishimaru zones 0-1 (Group 1), and 30% in patients with sealing in Ishimaru zones 2-3 (Group 2). Efficacy outcomes included MuVIT technical success and procedural technical success. Safety outcomes included MuVIT and procedural related complications in the first 30 days. RESULTS: During the study period 52 cases were screened for MuVIT. Of these, 40 patients (77%) underwent procedures that were performed under MuVIT. Exclusion reasons were local anaesthesia (n = 9); pulmonary contraindications (n = 2), and poor heart pump function (n = 1). Fifteen patients (37.5%) underwent bTEVAR, three patients (7.5%) fTEVAR, and 22 patients (55%) standard TEVAR. Twenty nine (72.5%) procedures were elective, seven (17.5%) were urgent, and four (10%) were as an emergency. Successful proximal endograft deployment under MuVIT was 100%. The target SBP reduction was achieved in 95% (Group 1: 89.5%, Group 2: 100%), with an overall mean reduction of 46% (Group 1: 55%, Group 2: 40%). The 30 day mortality was 7.5%, and was not MuVIT related. Two patients with COPD Gold III/IV developed respiratory complications. CONCLUSION: MuVIT is a safe and effective manoeuvre for CO reduction during aortic arch TEVAR. However, careful patient selection is required and potential adverse effects on patients with severe COPD needs further evaluation.
引用
- Stana J, Prendes CF, E Melo RG, et al. First Experience with the Munich Valsalva Implantation Technique (MuVIT) for Cardiac Output Reduction During Standard and Complex Thoracic Endovascular Aortic Repair. Eur J Vasc Endovasc Surg. 2022. PMID: 35487842. doi:10.1016/j.ejvs.2022.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。